Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HCAR2 | Q8TDS4 | 8/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | CYTH3 | O43739 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | EPN1 | Q9Y6I3 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 2/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69492 | 0.85 | MEN1 (0.58) | MEN1KMT2APOLBMAPTHCAR2 | |
| SCHEMBL20656278 | 0.84 | CDC7 (0.43) | MEN1KMT2APOLBCDC7PDPK1 | |
| Hydrochloric Acid SCHEMBL1221862 | 0.84 | MEN1 (0.57) | MEN1KMT2APOLBMAPTHCAR2 | |
| SCHEMBL70360 | 0.84 | CA12 (0.53) | MEN1KMT2APOLBMAPTHCAR2 | |
| SCHEMBL29019950 | 0.82 | MEN1 (0.51) | MEN1KMT2APOLBMAPTHCAR2 | |
| SCHEMBL19996893 | 0.81 | MEN1 (0.50) | MEN1KMT2APOLBMAPTHCAR2 | |
| SCHEMBL1413926 | 0.81 | MEN1 (0.54) | MEN1KMT2APOLBMAPTHCAR2 | |
| SCHEMBL1413865 | 0.81 | ALPL (0.53) | MEN1KMT2APOLBMAPTHCAR2 | |
| SCHEMBL1413993 | 0.81 | HCAR2 (0.55) | MEN1KMT2APOLBMAPTHCAR2 | |
| SCHEMBL70800 | 0.81 | RAB9A (0.55) | MEN1KMT2APOLBMAPTHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114685807-B | Cadmium coordination polymer based on pyrazole carboxylic acid ligand and preparation method thereof | 东南大学 | 2023-03-14 | — | — | CN | claimed |
| CN-114685807-A | Cadmium coordination polymer based on pyrazole carboxylic acid ligand and preparation method thereof | 东南大学 | 2022-07-01 | — | — | CN | claimed |
| CN-114685807-B | Cadmium coordination polymer based on pyrazole carboxylic acid ligand and preparation method thereof | 东南大学 | 2023-03-14 | — | — | CN | disclosed |
| CN-114685807-B | Cadmium coordination polymer based on pyrazole carboxylic acid ligand and preparation method thereof | 东南大学 | 2023-03-14 | — | — | CN | disclosed |
| CN-114685807-A | Cadmium coordination polymer based on pyrazole carboxylic acid ligand and preparation method thereof | 东南大学 | 2022-07-01 | — | — | CN | disclosed |
| CN-114685807-A | Cadmium coordination polymer based on pyrazole carboxylic acid ligand and preparation method thereof | 东南大学 | 2022-07-01 | — | — | CN | disclosed |
| CN-101910170-A | (1,4-diazabicyclo [3.2.2] ninth of the ten Heavenly Stems-6-alkene-4-yl)-heterocyclic radical-ketone part that is used for the treatment of the nicotinic acetylcholine receptor of disease | MEMORY PHARM CORP | 2010-12-08 | — | — | CN | disclosed |
| US-20100298306-A1 | (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2212321-A2 | (1,4-DIAZA-BICYCLO[3.2.2]NON-6-EN-4-YL)-HETEROCYCLYL-METHANONE LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, USEFUL FOR THE TREATMENT OF DISEASE | Memory Pharmaceuticals Corporation (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009055437-A9 | (1,4-DIAZA-BICYCLO[3.2.2]NON-6-EN-4-YL)-HETEROCYCLYL-METHANONE LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, USEFUL FOR THE TREATMENT OF DISEASE | MEMORY PHARM CORP (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009055437-A2 | (1,4-DIAZA-BICYCLO[3.2.2]NON-6-EN-4-YL)-HETEROCYCLYL-METHANONE LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, USEFUL FOR THE TREATMENT OF DISEASE | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298306-A1 | (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease | CHRNA7, CHRNA6, CHRNA5 | MEN1 2161/4885KMT2A 3050/4885POLB 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.